Investors poured into Moderna and Merck on Wednesday after the two pharmaceutical giants announced a major victory in their fight against skin cancer. A late stage clinical trial revealed that a personalized mRNA vaccine called intismeran, used in tandem with Merck’s immunotherapy drug Keytruda, significantly prevented melanoma from returning in high risk patients. The results sent shockwaves through the stock market, pushing Moderna shares toward a two year high and driving Merck to an all time peak.

Unlike standard cancer treatments that take a broad approach, this new therapy is entirely bespoke. Doctors surgically remove a piece of a patient’s tumor and sequence its DNA to find unique mutations. This information is then used to create a customized vaccine that trains the patient’s own immune system to hunt down and destroy any remaining cancer cells. According to Moderna President Stephen Hoge, this marks the first time an individualized treatment has shown such statistically significant improvement over existing checkpoint inhibitors like Keytruda alone.

The financial impact of the news was immediate and dramatic. Moderna saw its market capitalization jump by roughly 30 billion dollars as trading volumes skyrocketed far beyond their usual averages. The success also lifted the broader biotech sector, helping the Nasdaq Biotechnology Index climb to a record high as analysts grew optimistic about the future of personalized medicine.

Looking ahead, the companies have already begun talks with regulatory agencies and hope to bring the treatment to market as early as next year. While these current results focused on melanoma, Moderna and Merck are not stopping there. They are currently conducting further trials to see if this same tailored mRNA approach can be effectively used to treat other aggressive forms of cancer, including lung, pancreatic, and breast cancers.

To the casual observer, legendary resource investors seem to operate under the same pressures as everyone else. They endure grueling drawdowns, miss occasional trades, and engage in the same heated debates over macroeconomic trends that occupy every trading floor. However, insights shared at the 2026 Rule Symposium suggest that the true divide between a standard investor and a legend isn’t found in a secret list of winning stocks, but rather in a fundamental difference in psychological framing and portfolio architecture.

A recurring theme among veterans like Adrian Day and Jonathan Goodman is the concept of the circle of competence. Rather than chasing every hot tip, these investors focus on extreme honesty regarding what they do not know. While some leverage a generalist perspective to spot mispricings across different sectors, others emphasize that mining is far too complex for any single individual to master alone. Peter Grosskopf, chairman of SCP Resource Finance, noted that success often depends on building or accessing a specialized team capable of analyzing every technical dimension of a mine, arguing that without such support, an investor simply doesn’t stand a chance.

Perhaps the most sobering revelation came from Rick Rule regarding the actual experience of hitting a home run. According to Rule, his average ten-fold return took five and a half years to materialize and typically involved enduring a fifty percent drop in share price along the way. This highlights a brutal reality of the industry: massive gains require an appetite for volatility that goes beyond financial capacity and enters the realm of mental fortitude. For these experts, seeing a high-conviction stock crash by half isn’t a signal to exit; it is an invitation to buy three times as much.

This level of conviction is supported by rigorous discipline and an almost obsessive commitment to postmortem analysis. Instead of celebrating wins and forgetting losses, figures like Adrian Day meticulously study why certain plays failed to determine if it was bad luck or poor research. Furthermore, they maintain lean portfolios to ensure quality over quantity. By limiting their holdings to only those companies they have the hours available to properly track, they avoid the trap of owning a bit of everything while understanding nothing deeply. As Grosskopf warned, the greatest tragedy in mining isn’t picking several losers—it is selling your one true winner far too early before its full potential is realized.

A massive leap forward is taking place for one of Southeast Asia’s most elusive mineral treasures as Dominion Holdings moves to seize control of the Tampakan copper and gold project. Backed by the influential Sy and Consunji families, the company is orchestrating a complex three-way merger designed to absorb the operators of the site, effectively positioning Dominion to become the largest listed mining firm in the Philippines. To fuel this ambitious expansion, the company is significantly boosting its authorized capital stock to 30 billion pesos, with a final shareholder vote slated for September 2026.

The Tampakan deposit has been a subject of frustration and anticipation for three decades, remaining largely dormant due to regulatory hurdles and fierce local opposition. It famously saw global giant Glencore walk away in 2015 after a provincial ban on open-pit mining took effect, though that ban was eventually lifted in 2022. With current projections suggesting an annual output of 375,000 tons of copper and 360,000 ounces of gold over seventeen years, operations are now tentatively targeted for 2028. Road networks are already being constructed as part of the preparation phase.

Industry analysts suggest the stakes are astronomical, with some estimating the gross value of the reserves at between 150 billion and 200 billion US dollars. Beyond just profit, proponents argue that developing these resources would provide a massive boost to the national economy and solidify the country’s standing in the global resource sector. This move is part of a broader consolidation strategy by Dominion, which includes acquiring interests in Atlas Consolidated Mining and consolidating various holdings under one corporate umbrella.

However, the path toward production remains fraught with tension. Local religious leaders and community advocates continue to fight the project, citing grave environmental concerns in a region known as the food basket of Mindanao. In recent petitions to President Ferdinand Marcos Jr., critics have questioned the legality of previous contract extensions and warned that large-scale open-pit mining could devastate local ecosystems. As Dominion pushes forward with its financial restructuring, it must still navigate these deep-seated social and legal challenges before those billions in minerals can actually leave the ground.

The intersection of venture capital and clinical medicine is currently witnessing a profound transformation as artificial intelligence moves from theoretical promise to bedside application. While the overarching goal is a total overhaul of healthcare, investors are finding themselves navigating two very different speeds of innovation. On one hand, there are high-risk moonshots involving humanoid surgical robotics and synthetic genomics that require massive capital and years of patience. On the other, there are leaner, high-margin software plays focusing on emergency diagnostics and clinical trial efficiency that offer more immediate financial returns.

One of the most promising frontiers lies in diagnostic and screening platforms that shift medical care from crisis management to early intervention. Tokyo-based bio-AI firm Craif is a prime example, utilizing urinary microRNA to detect pancreatic cancer far earlier than traditional blood tests allow. With a recent Series D funding round pushing their total capital to roughly 88 million dollars, the company is aggressively expanding into the United States to scale its research in San Diego. Similarly, AI is proving vital in acute settings where seconds matter. Recent data published in the American Journal of Neuroradiology highlighted the efficacy of platforms like RapidAI and Viz.ai in detecting large vessel occlusions during strokes, emphasizing that real-world clinical validation is now the gold standard for investor confidence over simple marketing specifications.

Beyond direct patient care, AI is radically altering the economics of drug development by removing costly bottlenecks. Research conducted by the Tufts Center for the Study of Drug Development suggests that AI monitoring agents can slash Phase 3 trial operating costs by millions of dollars while shaving months off development timelines. For big pharma companies managing complex oncology programs, these operational efficiencies can translate into staggering returns on investment. This pragmatic approach exists alongside deeper scientific gambles, such as Xanadu Quantum Technologies partnering with Canadian universities to use quantum computing for designing next-generation tumor treatments via photodynamic therapy.

As AI evolves beyond screens and into physical forms, we are entering what some call a super-cycle of embodied AI and robotics. The boundaries of surgery were pushed further this year when researchers at the University of California San Diego performed live laparoscopic procedures using teleoperated humanoid robots on nonprimate mammals. While still in preclinical stages, these five foot tall machines signal a future where robotic precision integrates seamlessly into hospital infrastructure. From quantum chemistry to autonomous surgeons, capital is betting heavily that the fusion of silicon and biology will not just improve healthcare but entirely redefine it.

Mining giant BHP has teamed up with SiTration, a spin-out from MIT, to launch an ambitious pilot program in Arizona aimed at recovering copper from old mining wastewater. The project is centered at BHP’s Copper Cities facility within the Globe-Miami mining district, a site with a long history of production dating back to the mid-twentieth century. By targeting legacy assets, the partnership hopes to turn environmental liabilities into productive resources through a specialized extraction process.

The technology provided by SiTration claims to be a game changer for the industry because it can produce high grade copper without relying on harsh chemicals or creating additional waste. Early tests showed promising results, utilizing very low amounts of energy to achieve LME Grade A copper quality. The rollout will happen in stages, starting with a one month autonomous trial followed by a larger phase later this year intended to produce up to two tons of commercial scale copper cathodes.

This move comes at a critical time as global demand for copper skyrockets due to the expansion of power grids and the massive electrical needs of AI data centers. Industry experts suggest that annual demand could climb from 34 million tons today to 50 million tons by 2050. According to SiTration CEO Brendan Smith, the American Southwest contains billions of dollars worth of copper trapped in legacy water, offering a unique way to strengthen domestic supply chains while keeping costs extremely low.

For BHP, this venture aligns perfectly with its current corporate strategy. For the first time on an annual basis, copper has surpassed iron ore as the companies primary profit driver, contributing more than half of its total underlying earnings recently. As CEO Brandon Craig noted during recent financial presentations, copper has become the central engine driving BHPs overall growth and future expansion efforts globally.